Skip to Content

Tag: Sleep Apnea


Also Noted

AASM to pilot sleep scoring program

September 1, 2022HME News Staff

DARIEN, Ill. – The American Academy of Sleep Medicine has created a two-year pilot program to evaluate and certify software that uses auto-scoring functionality to score polysomnograms. The AI/Autoscoring Certification Program will independently verify the performance of auto-scoring systems. To obtain certification, the software must demonstrate accuracy that is equivalent or better than manual scoring. The pilot program is limited to sleep stage scoring. “Artificial intelligence technology...

American Academy of Sleep Medicine, Sleep Apnea


Read Full Articlered right arrow icon

SleepRes hires former Philips engineer 

Also Noted

SleepRes hires former Philips engineer 

July 22, 2022HME News Staff

NASHVILLE, Tenn. - SleepRes, developer of the V̇-Com, has announced Bernard Hete, PhD, as its chief technology officer to oversee future research and development. He was a senior engineer at Philips Respironics for 30 years. “Bernie [Dr. Hete] was always the smartest guy in the room, who always kept our ideas at Respironics to the laws of physics,” said Eugene Scarberry, a retired senior engineer at Philips who got the first FDA approval for CPAP back in 1985. “I have known Bernie...

accessory, CPAP Device, Sleep Apnea, SleepRes, V-Com


Read Full Articlered right arrow icon

Also Noted

RemSleep receives OTCQB status

July 13, 2022HME News Staff

TAMPA, Fla. – RemSleep Holdings has received approval to be uplisted to OTCQB status with otcmarkets.com. “This is a great milestone for RemSleep and our shareholders,” said Tom Wood, CEO. “We could not be more excited for where we are currently positioned and the trajectory of where we are going. Uplisting to OTCQB status provides next level accountability from us as a company with higher reporting standards and more comprehensive compliance requirements.” RemSleep...

RemSleep, Sleep Apnea


Read Full Articlered right arrow icon

Business Development

Sleep industry grapples with shortages

May 26, 2022John Andrews

While supply chain delays have been a major choke point for the U.S. economy over the past year, the recall of Philips Respironics’ flow generators and masks has compounded the obstruction in the sleep therapy market. The ensuing vacuum created by the recall caused a ripple effect throughout the marketplace, causing various suppliers to scramble for ways to cover the shortage.  At this point, suppliers are still frustrated by a hardscrabble supply line, but remain hopeful that product...

CPAP, CPAP recall, Philips Recall, Sleep Apnea, supply chain challenges


Read Full Articlered right arrow icon

Vendors

Sleep study questions adherence requirements 

May 19, 2022HME News Staff

SAN DIEGO – Sleep apnea sufferers can gain health benefits from PAP treatment in as little as two hours per night, according to a study led by ResMed and presented at the American Thoracic Society’s annual international conference.  Researchers found:  The minimum PAP usage threshold for benefit was two to three hours per night (up to 50% lower than the four hours required by CMS and many private insurers to prove adherence);  Benefits begin at two hours of nightly...

Adherence, PAP treatment, ResMed, Sleep Apnea


Read Full Articlered right arrow icon

Also Noted

Apnimed secures funding for OSA treatment

May 5, 2022HME News Staff

CAMBRIDGE, Mass. – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea and related disorders, has raised $62.5 million of committed capital in a Series C financing led by new investor Sectoral Asset Management. “Patients with obstructive sleep apnea are in need of new pharmaceutical treatment options to manage this serious, life-altering, and life-threatening disease,” said Larry Miller, M.D., CEO...

Apnimed, Sleep Apnea


Read Full Articlered right arrow icon

Also Noted

Oventus reaches milestone 

May 2, 2022HME News Staff

BRISBANE, Australia – Oventus Medical’s direct-to-consumer market model reached its first optimization milestone in the third quarter of its fiscal year 2022: It delivered growth in active leads with a reduction in advertising spend of 20% less than the previous quarter, the company has announced. Despite the March quarter being slow due to seasonality, Oventus says new leads increased 63% with 6,100 generated. “With the weakest of insurance seasonality period behind us, we...

Oral device, Oventus Medical, Sleep Apnea


Read Full Articlered right arrow icon

Also Noted

Oventus gains momentum with DTC model 

February 28, 2022HME News Staff

IRVINE, Calif. – Oventus Medical has reported interim financial results for the six months ended Dec. 31, 2021, including $554,000 in revenue. The company, which makes the O2Vent oral device to treat obstructive sleep apnea, also reported cash receipts totaling $497,000, up 20% compared to the same period in 2020. “We are very encouraged by the way the move to direct-to-consumer marketing has resulted in substantial growth of the prospective customer pipeline,” said John Cox, who...

O2Vent, Oral device, Oventus Medical, Sleep Apnea


Read Full Articlered right arrow icon

Also Noted

Study: CPAP for elderly patients not as effective

February 23, 2022HME News Staff

COLUMBIA, Mo. – CPAP therapy may not be as effective for patients older than 80, say researchers from the University of Missouri School of Medicine. In a study published in Sleep Medicine, researchers studied 369 participants over the age of 70 with OSA and assigned roughly half to receive CPAP therapy for three months. Researchers used several metrics to compare both groups, including a subjective measure of a patient’s sleepiness, the effect of CPAP on sleep-related quality of life,...

CPAP Therapy, Dr. David Gozal, Sleep Apnea


Read Full Articlered right arrow icon

Also Noted

RemSleep engages investor relations firm, news service

January 25, 2022HME News Staff

TAMPA, Fla. – RemSleep Holdings has partnered with Preya Co. and MCAP Mediawire to maximize its communication and exposure with current and potential shareholders, as well as refine and broaden its overall messaging and outreach. The move comes as the company prepares to get its DeltaWave nasal CPAP interface approved by the U.S. Food and Drug Administration and launched to market. “We feel we owe it to our current and future investors to have partnered with a gold star firm to assist...

nasal interface, RemSleep, Sleep Apnea


Read Full Articlered right arrow icon